01
Protein–protein interactions (PPIs) have evolved over millions of years to achieve highly selective partner recognition, ensuring precise and exclusive interactions within complex biological networks
02
Dysruptx harnesses the naturally evolved interface of a target PPI, mapping their uniquely selective binding characteristics
03
Applying these insights directly into the drug discovery process enables Dysruptx to develop Dysruptors, a class of macrocyclic peptide engineered to mimic and disrupt disease-driving PPIs with precision
04
De-risking Drug Development
By minimising off-target activity at the earliest stages of development, Dysruptors enable a precision targeted approach to treating human disease, dramatically minimising side-effect risk’
